Prospective Grant of an Exclusive Patent License: Interinstitutional Agreement-Institution Lead: Graphene Oxide-Polycarbonate Track-Etched Nanosieve Platform for Sensitive Detection of Human Immunodeficiency Virus Envelope Glycoprotein, 20507-20508 [2020-07707]
Download as PDF
<![CDATA[
20507
Federal Register / Vol. 85, No. 71 / Monday, April 13, 2020 / Notices
number of older adults have access to a
higher quality of life. Therefore, in
addition to the legislative mandate
under the OAA, it is important for
program integrity and function to
evaluate the LTCOP.
To comment and review the proposed
data collection please visit the ACL
effectively report its results to the
President, to Congress, to the
Department of Health and Human
Services and to the public.
The information will also aid in
program refinement and continuous
improvement. The more productive
ACL/AoA’s programs, the greater the
Respondent/data
collection activity
Estimated Program Burden
ACL estimates the burden associated
with this collection of information as
follows:
Responses
per
respondent
Hours per
response
Annual
burden hours
Focus Group—Facility staff including participant information .........................
Focus Group—Residents/family including participant information ..................
Interview—Stakeholders ..................................................................................
Survey—Facility Administrator .........................................................................
Survey—Former Ombudsmen .........................................................................
Survey—SUA director ......................................................................................
16
24
40
1840
12
53
1
1
1
1
1
1
0.33
1
1
0.33
1
0.5
5.3
24
40
607.2
12
26.5
Total: .........................................................................................................
1985
........................
4.16
715
Extramural Activities, National Institute of
Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room
3E71 Bethesda, MD 20892–9834, 301–761–
7749, lee.klinkenberg@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: April 6, 2020.
Mary Lazare,
Principal Deputy Administrator.
[FR Doc. 2020–07668 Filed 4–10–20; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
khammond on DSKJM1Z7X2PROD with NOTICES
Number of
respondents
website at https://www.acl.gov/aboutacl/public-input.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Statistical and Data
Coordinating Center (SDCC) for Clinical
Research in Infectious Diseases.
Date: May 11, 2020.
Time: 12:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3E71,
Rockville, MD 20892 (Telephone Conference
Call).
Contact Person: Lee G. Klinkenberg, Ph.D.,
Scientific Review Program, Division of
VerDate Sep<11>2014
17:57 Apr 10, 2020
Jkt 250001
Dated: April 7, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–07709 Filed 4–10–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Prospective Grant of an Exclusive
Patent License: Interinstitutional
Agreement—Institution Lead:
Graphene Oxide-Polycarbonate TrackEtched Nanosieve Platform for
Sensitive Detection of Human
Immunodeficiency Virus Envelope
Glycoprotein
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Indian Patent Applications listed in the
Supplementary Information section of
this notice to Chaudhary Charan Singh
Haryana Agricultural University
(CCSHAU) located in Hisar, India.
SUMMARY:
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Jasmine J. Yang, Ph.D.,
(Senior) Licensing and Patenting
Manager, NCI Technology Transfer
Center, 9609 Medical Center Drive, RM
1E530 MSC 9702, Bethesda, MD 20892–
9702 (for business mail), Rockville, MD
20850–9702 Telephone: (240)-276–5530;
Facsimile: (240)-276–5504 Email:
jasmine.yang@nih.gov.
ADDRESSES:
SUPPLEMENTARY INFORMATION:
National Institutes of Health
AGENCY:
Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before April 28, 2020 will be
considered.
DATES:
Intellectual Property
Indian Patent Application Serial No.
201711002764, filed February 24, 2017
entitled ‘‘Graphene oxide-polycarbonate
track-etched nanosieve platform for
sensitive detection of human
immunodeficiency virus envelope
glycoprotein.’’
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the CCS Haryana
Agricultural University and Government
of the United States of America as
represented by the Secretary,
Department of Health & Human
Services.
The prospective patent license will be
for the purpose of consolidating the
patent rights to CCSHAU, the co-owners
of said rights, for commercial
development and marketing.
Consolidation of these co-owned rights
is intended to expedite development of
the invention, consistent with the goals
E:\FR\FM\13APN1.SGM
13APN1
khammond on DSKJM1Z7X2PROD with NOTICES
20508
Federal Register / Vol. 85, No. 71 / Monday, April 13, 2020 / Notices
of the Bayh-Dole Act codified as 35
U.S.C. 200–212.
The prospective patent license will be
an exclusive in India and may be
limited to those fields of use
commensurate in scope with the patent
rights. It will be sublicensable, and any
sublicenses granted by CCSHAU will be
subject to the provisions of 37 CFR part
401 and 404.
This technology discloses a graphene
oxide-polycarbonate nanosieve
electrochemical biosensor for the
detection of HIV envelope glycoprotein.
The nanosieve is comprised of a
polycarbonate membrane layered with
graphene oxide laminate, which is
conjugated to a bispecific tetravalent
antibody, ‘‘2Dm2m’’, comprised of CD4
fused to a human domain targeting HIV–
1 coreceptor binding domain that has
high affinity to the HIV envelope
glycoprotein gp140. The nanosieve is
fitted between two Ag/AgCl electrodes
to form an electrochemical
nanobiosensor capable of detecting HIV
virus (see attached figures). Binding of
the HIV gp140 to 2Dm2m reduces the
ionic current through the nanosieve
biosensors, which functions as the
marker of HIV presence. The biosensor
has the potential to be a low-cost,
portable and quick method for HIV viral
load detection.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: April 2, 2020.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2020–07707 Filed 4–10–20; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:57 Apr 10, 2020
Jkt 250001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: AAV Mediated
Exendin-4 Gene Transfer to Salivary
Glands To Protect Subjects From
Diabetes or Obesity
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institute of
Diabetes and Digestive and Kidney
Disease and National Institute of Dental
and Craniofacial Research, institutes of
the National Institutes of Health,
Department of Health and Human
Services, are contemplating the grant of
an Exclusive Patent License to practice
the inventions embodied in the United
States, European and Canadian
Applications listed in the
Supplementary Information section of
this notice to Kriya Therapeutics, Inc.,
located in Palo Alto, California, USA.
DATES: Only written comments and/or
applications for a license which are
received by the National Institute of
Diabetes and Digestive and Kidney
Disease’s Technology Advancement
Office on or before April 28, 2020 will
be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Vladimir Knezevic, MD,
(Senior) Advisor for Commercial
Evaluation, Technology Advancement
Office, Building 12A, Room 3011,
Bethesda, MD 20817–5632 (for business
mail), Telephone: (301)–435–5560;
Email: vlado.knezevic@nih.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Intellectual Property
I. U.S. Pat: 9,511,103 issued 2016–12–
06, entitled ‘‘AAV mediated exendin-4
gene transfer to salivary glands to
protect subjects from diabetes or
obesity’’ (HHS Reference Number E–
142–2011–0–US–05).
II. U.S. Divisional Pat: 10,300,095
issued 2019–05–28, entitled ‘‘AAV
mediated exendin-4 gene transfer to
salivary glands to protect subjects from
diabetes or obesity’’ (HHS Reference
Number E–142–2011–0–US–6).
III. European Patent National Stage:
EP2709653 granted 2017–11–22,
entitled ‘‘AAV mediated exendin-4 gene
transfer to salivary glands to protect
subjects from diabetes or obesity’’ (HHS
Reference Number E–142–2011–0EP–
PO 00000
Frm 00042
Fmt 4703
Sfmt 9990
04), validated in Great Britain, France
and Germany.
IV. U.S. Patent Application No. 16/
396,262 filed 2019–04–26, entitled
‘‘AAV Mediated Exendin-4 Gene
Transfer to Salivary Glands to Protect
Subjects from Diabetes or Obesity’’
(HHS Reference Number E–142–2011–
0–US–10).
V. Canadian Application No.
2,833,623 filed 2012–04–19, entitled
‘‘AAV Mediated Exendin-4 Gene
Transfer to Salivary Glands to Protect
Subjects from Diabetes or Obesity’’
(HHS Reference Number E–142–2011–
0–CA–03).
The patent rights in these inventions
have been assigned or exclusively
licensed to the Government of the
United States of America.
The prospective exclusive license
territory may be worldwide and in fields
of use that may be limited to prevention
and treatment of type-2 diabetes and
obesity.
The above-listed patent portfolio
covers inventions directed to gene
therapy and specifically, expression
vectors and therapeutic methods of
using such vectors in the treatment of
type-2 diabetes and obesity.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing. The prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Institute of Diabetes and Digestive and
Kidney Disease receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially and may be made
publicly available.
License applications submitted in
response to this notice will be presumed
to contain business confidential
information and any release of
information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: April 1, 2020.
Vladimir Knezevic,
Senior Advisor for Commercial Evaluation,
Technology Advancement Office, National
Institute of Diabetes and Digestive and Kidney
Disease.
[FR Doc. 2020–07706 Filed 4–10–20; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\13APN1.SGM
13APN1
]]>Agencies
[Federal Register Volume 85, Number 71 (Monday, April 13, 2020)]
[Notices]
[Pages 20507-20508]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-07707]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License:
Interinstitutional Agreement--Institution Lead: Graphene Oxide-
Polycarbonate Track-Etched Nanosieve Platform for Sensitive Detection
of Human Immunodeficiency Virus Envelope Glycoprotein
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an Exclusive Patent License to practice the
inventions embodied in the Indian Patent Applications listed in the
Supplementary Information section of this notice to Chaudhary Charan
Singh Haryana Agricultural University (CCSHAU) located in Hisar, India.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before April 28, 2020 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an Exclusive Patent License
should be directed to: Jasmine J. Yang, Ph.D., (Senior) Licensing and
Patenting Manager, NCI Technology Transfer Center, 9609 Medical Center
Drive, RM 1E530 MSC 9702, Bethesda, MD 20892-9702 (for business mail),
Rockville, MD 20850-9702 Telephone: (240)-276-5530; Facsimile: (240)-
276-5504 Email: [email protected].
SUPPLEMENTARY INFORMATION:
Intellectual Property
Indian Patent Application Serial No. 201711002764, filed February
24, 2017 entitled ``Graphene oxide-polycarbonate track-etched nanosieve
platform for sensitive detection of human immunodeficiency virus
envelope glycoprotein.''
The patent rights in these inventions have been assigned and/or
exclusively licensed to the CCS Haryana Agricultural University and
Government of the United States of America as represented by the
Secretary, Department of Health & Human Services.
The prospective patent license will be for the purpose of
consolidating the patent rights to CCSHAU, the co-owners of said
rights, for commercial development and marketing. Consolidation of
these co-owned rights is intended to expedite development of the
invention, consistent with the goals
[[Page 20508]]
of the Bayh-Dole Act codified as 35 U.S.C. 200-212.
The prospective patent license will be an exclusive in India and
may be limited to those fields of use commensurate in scope with the
patent rights. It will be sublicensable, and any sublicenses granted by
CCSHAU will be subject to the provisions of 37 CFR part 401 and 404.
This technology discloses a graphene oxide-polycarbonate nanosieve
electrochemical biosensor for the detection of HIV envelope
glycoprotein. The nanosieve is comprised of a polycarbonate membrane
layered with graphene oxide laminate, which is conjugated to a
bispecific tetravalent antibody, ``2Dm2m'', comprised of CD4 fused to a
human domain targeting HIV-1 coreceptor binding domain that has high
affinity to the HIV envelope glycoprotein gp140. The nanosieve is
fitted between two Ag/AgCl electrodes to form an electrochemical
nanobiosensor capable of detecting HIV virus (see attached figures).
Binding of the HIV gp140 to 2Dm2m reduces the ionic current through the
nanosieve biosensors, which functions as the marker of HIV presence.
The biosensor has the potential to be a low-cost, portable and quick
method for HIV viral load detection.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: April 2, 2020.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2020-07707 Filed 4-10-20; 8:45 am]
BILLING CODE 4140-01-P
